Protein Kinase Cβ Is an Effective Target for Chemoprevention of Colon Cancer
Open Access
- 12 February 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (4), 1643-1650
- https://doi.org/10.1158/0008-5472.can-08-3187
Abstract
Colon cancer develops over a period of 10 to 15 years, providing a window of opportunity for chemoprevention and early intervention. However, few molecular targets for effective colon cancer chemoprevention have been characterized and validated. Protein kinase CβII (PKCβII) plays a requisite role in the initiation of colon carcinogenesis in a preclinical mouse model by promoting proliferation and increased β-catenin accumulation. In this study, we test the hypothesis that PKCβII is an effective target for colon cancer chemoprevention using enzastaurin (LY317615), a PKCβ-selective inhibitor, in a mouse model of colon carcinogenesis. We find that enzastaurin potently reduces azoxymethane-induced colon tumor initiation and progression by inhibiting PKCβII-mediated tumor cell proliferation and β-catenin accumulation. Biochemically, enzastaurin reduces expression of the PKCβII- and β-catenin/T-cell factor–regulated genes PKCβII, cyclooxygenase II, and vascular endothelial growth factor, three genes implicated in colon carcinogenesis. Our results show that enzastaurin is an effective chemopreventive agent in a mouse model of sporadic colon cancer that significantly reduces both tumor initiation and progression by inhibiting expression of proproliferative genes. Thus, PKCβII is an important target for colon cancer chemoprevention and the PKCβ-selective inhibitor enzastaurin may represent an effective chemopreventive agent in patients at high risk for colon cancer. [Cancer Res 2009;69(4):1643–50]Keywords
Other Versions
This publication has 50 references indexed in Scilit:
- Protein Kinase C βII and PKCι/λ: Collaborating Partners in Colon Cancer Promotion and ProgressionCancer Research, 2009
- Atypical Protein Kinase Cι Expression and Aurothiomalate Sensitivity in Human Lung Cancer CellsCancer Research, 2008
- Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasisInvestigational New Drugs, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray AnalysisCancer Research, 2007
- Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Blood, 2006
- Prostaglandin E2 Stimulates the β-Catenin/T Cell Factor-dependent Transcription in Colon CancerJournal of Biological Chemistry, 2005
- Protein Kinase CβII Regulates Its Own Expression in Rat Intestinal Epithelial Cells and the Colonic Epithelium in VivoPublished by Elsevier BV ,2004
- Role of Cyclooxygenase 2 in Protein Kinase C βII-mediated Colon CarcinogenesisJournal of Biological Chemistry, 2003
- Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3βCurrent Biology, 1998